CD160 and neoplasm: Within the tumours of treated animals, CTLA-4 blockade gave rise to a significantly altered expression of markers associated with dysfunction (PD-1, Lag-3 and CD160), activation (CD25, GITR and CD38), as well as co-stimulation and development (CD27 and CD127) on mLama4-specific T cells.